Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation

Nephrology Dialysis Transplantation

Volumn 15, Issue 8, 2000, Pages 1228-1231

  Wüthrich, Rudolf P ^a,b   Cicvara, Snjezana ^a   Ambühl, Patrice M ^a   Binswanger, Ulrich ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

CsA dosage; Low risk kidney transplant recipients; Mycophenolate mofetil to azathioprine conversion; Prednisone; Short term graft survival; Six month trial

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FUNCTION TEST; KIDNEY GRAFT REJECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SIDE EFFECT; TREATMENT FAILURE;

EID: 0342626739     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.8.1228     Document Type: Article

References (9)

1. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232
2. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325
3. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037
4. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C, for the International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997; 63: 39-47
5. Wiesel M, Carl S for the European Mycophenolate Mofetil Cooperative Study Group. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. J Urol 1998; 159: 28-33
6. Kim YS, Moon JI, Kim SI, Park K. Clear benefit of mycophenolate mofetil-based triple therapy in reducing the incidence of acute rejection after living donor renal transplantations. Transplantation 1999; 68: 578-581
7. Wüthrich RP, Weinreich T, Ambühl PM, Schwarzkopf AK, Candinas D, Binswanger U. Reduced kidney transplant rejection rate and pharmaco-economic advantage of mycophenolate mofetil. Nephrol Dial Transplant 1999; 14: 394-399
8. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391-396
9. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 1999; 34: 296-303